Medical Condition News

RSS

Some HIV drugs can cause premature ageing

A class of anti-retroviral drugs commonly used to treat HIV, particularly in Africa and low income countries, can cause premature ageing, according to research published today in the journal Nature Genetics. The study shows that the drugs damage DNA in the patient's mitochondria - the 'batteries' which power their cells.

27 Jun 2011

Diabetic patients can benefit from basal insulin analogs

Basal insulin analogs have revolutionized diabetes care, and especially the treatment of type 2 diabetes, enabling patients to achieve better control of blood glucose levels while reducing hypoglycemic episodes.

27 Jun 2011

Short-term lowering of PreDx DRS may reduce risk of developing diabetes

Data presented today from an analysis of samples from the European Diabetes Prevention Study (EDIPS) showed that the PreDx Diabetes Risk Score (DRS) is lowered by lifestyle intervention, which correlates to a reduction in the risk that patients will develop diabetes over time.

27 Jun 2011

Diabetes more prevalent in every part of the world

A major international study collating and analyzing worldwide data on diabetes since 1980 has found that the number of adults with the disease reached 347 million in 2008, more than double the number in 1980. The research, published today in The Lancet, reveals that the prevalence of diabetes has risen or at best remained unchanged in virtually every part of the world over the last three decades.

27 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

Why breakfast with a friend could be just what the doctor ordered

Spending too much time alone and regularly skipping breakfast might be pushing you closer to heart disease, warns the National Heart Foundation of Australia.

26 Jun 2011

Isotechnika's partner Lux to appeal EMA CHMP decision against Luveniq

Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc. will appeal the European Medicines Agency's (EMA) decision not to approve Luveniq™ (voclosporin) as a treatment for noninfectious uveitis involving the intermediate or posterior segments of the eye.

24 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

Experts discuss global threat of Alzheimer's disease at House subcommittee hearing

"Alzheimer's experts urged U.S. lawmakers on Thursday to increase funding for research of the debilitating disease and to push international policymakers to pay more attention to its global impact," Reuters reports (Steenhuysen, 6/23).

24 Jun 2011

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

Shire plc, the global specialty biopharmaceutical company, today announced that the European Medicines Agency has approved the purification of REPLAGAL® (agalsidase alfa) drug substance at its new manufacturing facility in Lexington, MA, US. REPLAGAL, Shire's enzyme replacement therapy for the treatment of Fabry disease is the first product that will be made available to patients from the new facility.

24 Jun 2011

EMA CHMP recommends approval of linagliptin for type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.

24 Jun 2011

Less than half of primary-care physicians refer all diabetes patients to education programs

While studies have shown that diabetes education programs are crucial in helping individuals living with the disease self-manage their condition, a new study led by Ryerson researchers has found that less than half of primary-care physicians surveyed refer all of their patients with diabetes to these programs.

24 Jun 2011

New model of health care delivery relies on active participation of patients and caregivers

A new model of care developed for patients at the Myeloma Institute for Research and Therapy at the University of Arkansas for Medical Sciences (UAMS) has led to improved patient experience, lower costs and better patient outcomes.

24 Jun 2011

Disordered eating behaviors carried into young adulthood and beyond

Adolescents who diet and develop disordered eating behaviors (unhealthy and extreme weight control behaviors and binge eating) carry these unhealthy practices into young adulthood and beyond, according to a study conducted by University of Minnesota researchers and published in the July 2011 issue of the Journal of the American Dietetic Association.

24 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Bodies resist weight loss efforts when food intake is reduced drastically

If you've been trying to lose weight and suspect your body's working against you, you may be right, according to a University of Illinois study published in Obesity.

24 Jun 2011

Pfizer and Pain Therapeutics receive FDA Complete Response Letter for resubmission of REMOXY NDA

Pfizer and Pain Therapeutics, Inc. announced that a Complete Response Letter was received from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them.

24 Jun 2011

Epilepsy may arise from complex mixture of altered ion channels

Imagine two flat screen televisions tuned to the same channel and sitting side-by-side. From a distance, their pictures are virtually the same, however up close, you can see subtle variations in the pixels - one blurred here, another dropped out there.

24 Jun 2011

ABA honors Acorda Therapeutics president with 2011 Stevie Award

Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, was awarded the 2011 Stevie Award for Executive of the Year in the Health Products & Services category at the 9th Annual American Business Awards (ABA) ceremony held on June 20, 2011.

24 Jun 2011

Leaky blood vessels may cause sepsis rather than a symptom: Research

Researchers at St. Michael's Hospital have put forward a new theory as to what causes sepsis, an often fatal condition that occurs when infection spreads throughout the body.

24 Jun 2011